1st International Congress on Clinical Research with Biopharmaceutical Products
WELCOME
We are pleased to invite you to attend the 1st International Congress on Clinical Research with Biopharmaceutical Products, Clinical Biopharm 2025, which will take place from October 20 to 24, 2025, at the Meliá Internacional Varadero Hotel, Matanzas, Cuba.
It will be a space where clinical specialists, scientists, businessmen, and opinion leaders will exchange their experiences and update their knowledge on clinical research involving innovative therapeutic products. The program will include a broad scientific focus on advances in oncology in the prevention, diagnosis, and treatment of cancer; research into interferons, cytokines, and other biopharmaceuticals; and clinical evaluations in autoimmune, cardiovascular, neurodegenerative, and cerebrovascular diseases, among others.
On this occasion, three symposia will showcase results of scientific and social impact resulting from the clinical development of biopharmaceutical industry products:
Symposium No. 1: Clinical applications of interferons.
- Historical perspective of Cuban clinical trials on interferons (IFNs).
- Present and future of Cuban clinical research on IFNs in Cancer and infectious diseases
- Pediatric use of IFNs.
Symposium No. 2: Advances in Clinical Cancer Research. 1st National Workshop on Clinical Cancer Research with Biopharmaceutical Products.
New targets and challenges in clinical trials with molecular therapeutics and immunotherapy:
- Educational Intervention in Cancer Patients.
- Methodologies for the design and approach to oncological clinical trials.
- Implementing Cancer Prevention and diagnostics into Clinical Practice.
- Advances in Technologies, radiation and imaging in Oncology clinical Trials.
- Clinical Trials with Biopharmaceutical Products in Oncology.
- Regulatory landscape for oncology clinical trials.
Symposium No. 3: Advances in clinical research of biotechnological products for the management of chronic non-communicable diseases.
- Clinical trials of new biotechnology therapies and treatments.
- Regulation and approval of biotechnology products.
- Advances in the diagnosis and monitoring of chronic diseases.
- Impact of biotechnology therapies on public health.
- Collaborations between academia and industry.
The symposium will highlight clinical outcomes and innovative approaches related to: a) cardiac and cerebrovascular diseases; b) chronic lower respiratory tract diseases; c) neurodegenerative disorders (with an emphasis on Alzheimer’s disease and other dementias, Parkinson’s disease, and cerebellar ataxias); d) diabetes; e) nephritis, nephrotic syndrome, and nephrosis; f) chronic liver disease and cirrhosis; g) autoimmune diseases; other chronic non-communicable diseases; and advanced diagnostic techniques for chronic non-communicable diseases.
We look forward to your valuable presence at Cuba’s most famous resort to promote the advancement and development of scientific research in these fields.
We respectfully request the financial collaboration of your entity to enhance the success of this congress:
Organizing Committee
Instructions for abstracts of oral and poster presentations
Abstracts should be sent by email to clinicalbiopharm2025@cigb.edu.cu and will be published in the book of abstracts.
Abstracts (for oral and poster presentations) must follow the following instructions:
– Format: Acceptable file formats include .doc, .docx, and .rtf, Please do not upload .pdf files.
– Font and spacing: Arial 10-point font, single-spaced.
– Title: Title must be centered, bold, and capitalized only with the initial letter. It should not exceed 130 characters (not including spaces).
– Authors: Without including the word “authors,” each author’s first name (and middle initial, if applicable) and last name should appear, along with a superscript number identifying the author’s affiliation (e.g., Katty H. Vaillant1, John Smith2). The maximum number of authors is 20. The presenting author should appear in bold and underlined. Alignment: Justified.
– Affiliations: List (institution, city, and country) consecutively, separated by semicolons. (e.g., 1) Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba; 2) San Pedro University Hospital, Logroño, Spain).
– Abstract text: It is structured and consists of the following sections: Introduction, Objective, Method, Results, and Conclusions. The maximum length should not exceed 300 words (excluding section headings). Do not include tables, figures, or graphs. The abstract text should be aligned justified.
– Contact: Full name, institution of origin, and email address are required; this information should appear below the summary.
– Presentation Method: Specify, at the end of the abstract, your preferred presentation method (oral or poster). The Scientific Committee reserves the right to determine the presentation method for each symposium and will notify the author in due course. Poster presentations will be submitted electronically.
Copyright: The Organizing Committee will consider all papers to have been authorized for presentation at the Congress by all individuals and institutions that participated in or funded them. All responsibility for any conflicts of interest that may arise rests with the presenting autor.
Language: Abstracts of oral and poster presentations must be written in English.
Deadline for abstract submission: August 31, 2025
Acceptance deadline: September 20, 2025
Registration Fee
| Sector | Until June 30, 2025 | From 30 June 2025 |
| Private sector | 750 USD | 800 USD |
| Academics | 550 USD | 600 USD |
| Students | 350 USD | 400 USD |
| Companions | 350 USD | 400 USD |
The registration fee includes:
- Identification card.
- Attendance at the conference’s scientific activities.
- Scientific program and abstracts (digital).
- Certificate of attendance.
- Welcome cocktail and coffee breaks during the conference sessions.
To pay:
https://clinical-biopharm.cubagrouplanner.com/en/info_pyth/show_info
Sponsors
